Will JUUL Relaunch Mint? Market Drops to 28% Amid FDA Silence

---

JUUL's Mint Flavor Still Leads the Market — So Why Are Its Odds Collapsing?

JUUL Labs has not added a single flavor to its U.S. product lineup since the FDA permitted the company to continue selling tobacco and menthol e-cigarettes in July 2025. The calendar now reads July 28, 2026. Five months remain before this prediction market resolves on December 31, and the company's American shelves still carry exactly two options: Virginia Tobacco and Menthol. No Mint. No timeline for Mint. No public indication that Mint is even in the regulatory pipeline.

Prediction-market view

Live prices, venue by venue

Compare the latest YES price at each venue. Check market rules, liquidity, and fees before trading.

Mint

Consensus YES price across 1 venues

15%average

KalshiBest YES price16¢

Mango

Consensus YES price across 1 venues

6%average

KalshiBest YES price9¢

Cucumber

Consensus YES price across 1 venues

1%average

KalshiBest YES price9¢

Mint

Consensus YES price across 1 venues

52%average

PolymarketBest YES price98¢

The market has noticed. Mint's implied probability of relaunch sits at 28%, down from 38% just three days ago. That 10-percentage-point drop is the sharpest recent move in the "What flavors will JUUL relaunch?" market tracked across Kalshi and Polymarket. Yet Mint still leads every other flavor in the field. No competitor has surged to fill the vacuum. This is not a rotation into a rival candidate. It is a broad repricing of whether JUUL will expand beyond its current two-flavor footprint at all before year-end.

The exact catalyst for the three-day sell-off is unclear. No confirmed breaking news event within the 72-hour window explains the move on its own. The accumulation of negative evidence, rather than a single headline, appears to be doing the work. Traders are connecting dots that have been visible for months.

---

The FDA Signal Hidden in JUUL's Relaunch Strategy That Markets Are Finally Pricing

The most telling data point is not a news story. It is a regulatory filing. In May 2026, JUUL Labs submitted comments to the FDA's draft guidance on flavored e-cigarettes, framing flavors as a cessation tool for adult smokers transitioning away from combustible cigarettes. The language was careful, academic, and policy-oriented. It read like a company building a long-term regulatory argument, not one preparing a near-term product launch.

This distinction matters enormously. The FDA's authorization framework for flavored e-cigarettes requires manufacturers to demonstrate that the public health benefit of a flavor outweighs its risk of attracting youth. Mint and menthol-adjacent profiles face especially intense scrutiny because the FDA has spent years attempting to ban menthol in combustible cigarettes, a process stalled in litigation but signaling the agency's directional hostility toward cooling flavors. JUUL's own 2022 near-death experience, when the FDA ordered all its products off the market before a court stay intervened, looms over every authorization calculation. Mint was never part of the product set that ultimately received clearance.

Meanwhile, the FDA authorized fruit-flavored vapes from another manufacturer in May 2026, proving the agency is willing to greenlight non-tobacco flavors under the right evidentiary package. That precedent helps the broader flavor market but does not automatically help JUUL, whose regulatory history is uniquely fraught. The company would need to file a standalone Premarket Tobacco Product Application for Mint, survive the review process, and receive authorization, all within roughly 155 days. There is no public evidence that such an application has been filed.

Internationally, JUUL expanded its JUUL2 lineup in the UK with a peach-flavored cartridge in January 2026. This shows the company retains the operational capability and commercial desire to sell flavored products. But the UK regulatory environment bears no resemblance to the FDA's PMTA process. What works in London tells us nothing about what the FDA will permit in the United States.

---

The Case FOR Mint's Comeback: What Would Have to Be True for the Market to Be Wrong

Dismissing Mint at 28% requires ignoring some stubborn commercial realities. Before the FDA crackdown, Mint was JUUL's best-selling flavor by a wide margin, driving a disproportionate share of the company's revenue. No rational actor with JUUL's balance sheet and market position would voluntarily abandon that revenue permanently. The question is not whether JUUL wants to sell Mint. It is whether the regulatory window opens in time.

Here is where the bull case gets interesting. The FDA's May 2026 authorization of fruit-flavored vapes from a competing manufacturer established a live precedent for flavored product approvals. If JUUL has been quietly building its PMTA submission for Mint, using the cessation-tool framework it articulated in its May comments as the evidentiary backbone, the timeline is tight but not impossible. FDA review periods for tobacco products have occasionally compressed to weeks when political or public health urgency aligns.

There is also regulatory ambiguity working in Mint's favor. Menthol and mint occupy a legally contested zone. The FDA's proposed ban on menthol in combustible cigarettes has been delayed repeatedly, most recently by litigation that has pushed any final rule well into the future. This limbo creates a paradox: the agency cannot coherently ban menthol cigarettes while simultaneously blocking a mint-flavored vaping product that serves as a cessation alternative to those same cigarettes. A savvy JUUL legal team could exploit that tension.

At 28%, the market is pricing in roughly a one-in-four chance that JUUL clears these hurdles before December 31. That is a meaningful probability accounting for both the commercial incentive and the regulatory headwinds. Mint's drop from 38% reflects the market absorbing real information about JUUL's pace and posture, not panic. But the floor may be closer than bears think. The period low of 21% suggests sellers have already tested lower levels and found buyers willing to defend the position.

The core tension remains unresolved: JUUL's words say flavors matter for public health, but its actions say Virginia Tobacco and Menthol are enough for now. Until the company files, announces, or launches, Mint's 28% will keep drifting on inference rather than evidence. Five months is a long time in regulatory politics. It is a short time in FDA review cycles. That gap is exactly what makes this market worth watching.